drugset / Trial / NCT00871741
Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.
RandomizedParallel-groupOpen-labelPrevention
Summary
This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083A vaccine given as a three-dose vaccination course at 3, 5 and 11 months of age.
Timeline
- Start
- 2009-04-01
- Primary completion
- 2009-06-25
- Completion
- 2009-06-25
Outcome
Outcome not reported
Stopped: “Study stopped due to non-approval of IEC to proposed change in locations. Study discontinuation not due to safety/efficacy reasons related to the vaccine.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK2202083A | Vaccine | — | Intramuscular |
| Comparator | Infanrix hexa | Vaccine | — | Intramuscular |
| Comparator | Menjugate | Vaccine | — | Intramuscular |